US biotechnology company Lentigen Corporation announce exclusive licensing agreement with Cambridge Enterprise for a fundamental patent in lentiviral vector technology developed by Professor Andrew Lever at the University of Cambridge.
Lentigen licenses fundamental lentiviral vector technology patent from the University of C...
“The patent broadly claims fundamental compositions of HIV-based lentiviral vectors that are currently widely used in research and clinical studies,” said Boro Dropulic, PhD, Founder, President and Chief Scientific Officer of Lentigen. He added “We are delighted to be working with Professor Lever in obtaining this patent licence, and developing its application in biomedicine.”
Following the acquisition of the Cell Genesys’ lentiviral patent portfolio late last year by GBP Capital, the majority shareholder in Lentigen, this licence further consolidates Lentigen’s intellectual property position.
“Licensing this fundamental technology patent from the University of Cambridge extends our strong intellectual property position and is consistent with our goal of becoming a leader in lentiviral-vector based biomedicine. It further enables Lentigen to pursue development and commercialisation of biomedical products and services, to the benefit of patients, healthcare providers and the research community,” said Tim Ravenscroft, Chief Executive Officer of Lentigen.
“Lentigen are the ideal partner for this piece of fundamental lentiviral vector technology. We are pleased to be working with a team committed to developing the technology for patient benefit,” added Dr Andrew Walsh, Technology Manager for Cambridge Enterprise, University of Cambridge.
Lentiviral vectors (LV) are the most efficient vehicles for stable delivery of genes or gene silencing sequences (e.g. RNAi) into cells. Gene delivery is accomplished by the binding and fusion of the LV pseudotyped envelope protein to the target cell membrane. The LV genomic RNA comprising the gene or gene silencing sequence is then converted to DNA and permanently integrates into the cell’s genome with extraordinary high efficiency. The gene or gene silencing sequence is then expressed in the cells, resulting in cells that are permanently genetically engineered with the desired effect.
Lentigen Corporation is a privately owned biotechnology company focused on the development of lentiviral vector technology for a wide range of therapeutic, vaccine, and research applications in biotechnology and medicine. Lentiviral vectors are the most efficient vehicles for the delivery of genes or gene silencing sequences stably into cells. Lentigen is a highly collaborative company, co-developing lentiviral vector-based products across a broad spectrum of bench to clinical applications. Partnerships include The National Institutes of Health, The University of Pennsylvania, ThermoFisher Scientific and The U.S. Army. For further information, visit www.lentigen.com
Cambridge Enterprise exists to help University of Cambridge inventors, innovators and entrepreneurs make their ideas and concepts more commercially successful for the benefit of society, the UK economy, the inventors and the University.